Light blue incomplete circle.

about us

Pathos is redefining DRUG DEVELOPMENT starting IN Oncology.

By combining large-scale multimodal patient data with proprietary AI, Pathos helps identify which patients are most likely to benefit, increasing probability of success and accelerating high confidence Go/No-Go decisions.

Black circle on a white background.
Black circle on a white background.
Black circle on white background.
Black circle on white background.
Black circle on a white background.

the result?

A scalable, repeatable, patient-centered model for drug development that delivers smarter treatments, greater success, and stronger investor returns.

Gradient background of light blue fading to white.

who we are

pathos core values

Teal dots arranged in a roughly hexagonal shape, forming a cluster.

integrity

Data-driven, transparent decisions that put science first.

Dots arranged in a pattern, with several clusters and a few isolated dots.

innovation

Harnessing AI and multimodal data to build a smarter model for drug development.

Dark teal dots arranged in a stylized, swirling shape, resembling two interlocking spirals.

collaboration

Partnering with pharma, biotech, academia, and investors to bring therapies to patients.

Arrangement of teal dots in a column pattern, resembling a stylized shape.

resilience

Persevering through setbacks to deliver lasting progress in oncology.

A pattern of teal dots radiating outwards from a central cluster.

empathy

Shaped by lived cancer experience; we lead with humanity.

Our mission starts with people. Join the team transforming how new therapies are developed, bringing better treatments to the patients that need them most.

Vertical white lines pattern.

The Pathos Story

Pathos was founded at the intersection of technology, oncology, and lived experience.

Pathos was founded in 2022 by Eric Lefkofsky and Ryan Fukushima, after they realized that AI could have a profound impact on drug discovery and development. In 2025, Iker Huerga, cancer survivor and biotech veteran, joined as CEO to focus on one mission: get the right therapies to the right patients, sooner.

Illustration:

Drawing on decades of leadership at Tempus and AstraZeneca, Pathos recognized that combining millions of patient records with proprietary AI could rewrite that story.


Today, Pathos uses this model to identify the right patients, design adaptive trials, and run them with small AI-enabled teams.

Each program teaches the next — making the system faster, smarter, and more precise.

mission & vision

Our mission is to transform drug development using proprietary patient data and AI to dramatically improve trial success rates and bring new hope to patients who fail traditional therapies.

Black circle on a white background.
Black circle on white background.
Black circle on a white background.

We see a future where every patient has a real chance at the right treatment because drug development is data-guided, patient-centered, and repeatable. A new standard for how therapies are discovered, tested, and delivered.

The Future of Pathos

Pathos is building the blueprint for a new era of biopharma, one where data, intelligence, and humanity work in concert.

Text labels

In this future, every trial begins with clarity.

Where drug development is no longer a gamble but a guided science, a living system that improves with every discovery.


For patients, it means more hope. For partners, it means more certainty. For the industry, it means transformation from reactive to intelligent, from incremental to exponential.

White background.
Empty white image.

Learn more about our Platform

This is the path forward. This is the future Pathos is building.

Empty white space.

Learn more about our Platform

This is the path forward. This is the future Pathos is building.

our team

Together, we’re redefining what’s possible in drug development, turning data into discovery, and discovery into hope.

Light blue dot pattern, vertically aligned with slight variations.

Leadership

Board of Directors

The Team

Leadership Team

Man with short dark hair in a jacket, looking directly at the viewer. Black and white.

Iker Huerga

CHIEF EXECUTIVE OFFICER AND BOARD MEMBER

Iker Huerga is the Chief Executive Officer of Pathos AI, where he leads the company’s mission to transform drug development through artificial intelligence. A seasoned biotech entrepreneur and AI leader, Iker brings over two decades of experience at the intersection of machine learning and oncology. Prior to joining Pathos, he served as Chief Data Scientist for Oncology R&D at AstraZeneca and as EVP at Tempus Labs. He has founded and successfully exited multiple AI-driven oncology startups and is recognized for pioneering work in applying multimodal AI to clinical trial design, biomarker discovery, and precision medicine.

Man wearing a polo shirt smiles at the camera. Black and white, studio shot.

Eric Schadt, Ph.D.

CHIEF SCIENCE OFFICER

Eric Schadt joined Pathos as Chief Scientific Officer and maintains a continuing faculty role at the Icahn School of Medicine at Mount Sinai (ISMMS). Prior to joining Pathos, Schadt was founding CEO and then chief R&D officer of Sema4 (now GeneDx), a next-generation, information-driven precision medicine company developing advanced genomic testing solutions to enable genomic medicine.


He has also served as chairman of the Department of Genetics and Genomic Sciences and founding director of the Icahn Institute for Genomics and Multiscale biology at ISMMS (2012-2018), as CSO of Pacific Biosciences (2009-2011), and varying scientific leadership roles at Merck, Rosetta Inpharmatics, and Roche.


Schadt has his undergraduate training in computer science and math from Cal Poly, San Luis Obispo, a Master’s in Pure Mathematics from UC Davis, and a PhD in Biomathematics from UCLA. He is considered a pioneer in developing and applying integrative computational biology methods to very large-scale data to further our understanding of disease and wellness (co-author of more than 500 peer-reviewed papers and an h-index of 146).

Man with glasses smiles, looking forward; wearing a dark button-down shirt.

Matt De Silva

CHIEF OPERATING OFFICER

Matt De Silva joined Pathos as Chief Operating Officer. Previously he was founder and chairman of Notable Labs, a clinical-stage precision therapeutics company developing predictive ex vivo technology to identify, from a blood sample taken before treatment, whether a patient will positively respond to a given treatment. He is also currently a Venture Partner at Builders VC, a Series A and seed-focused venture firm based in San Francisco. De Silva focuses on the healthcare and life science investment practice.


Prior to Notable, which he ran as CEO from 2014 to 2020, he was a macro hedge fund portfolio manager at Peter Thiel’s family office Thiel Capital. Prior to Thiel Capital, De Silva was an analyst at Bank of America Merrill Lynch. He graduated from Cornell University in Applied Economics and Management and was the captain of the cross country team.

board members

Smiling man with glasses and blazer against a wood background.

Ryan Fukushima

COFOUNDER AND BOARD MEMBER

Man with glasses smiles, looking at camera. Dark shirt, monochrome studio portrait.

Eric Lefkofsky

COFOUNDER AND CHAIRMAN

Man in a suit smiles at the camera, headshot.

Amit Mehta

BOARD MEMBER

Man in a blazer smiling at the camera, short dark hair, full beard, neutral background.

Mohamad Makhzoumi

BOARD MEMBER

Explore career opportunities

If you’re driven by purpose, grounded in science, and inspired by impact, we want to hear from you.

Black arrow pointing to the right.